Candidiasis
Candidiasis is an infectious disease caused by a variety of pathogenic Candida species and is most common in people with weakened immune systems. It can also affect the local skin, mucus membranes, and various tissues and organs of the body. We have the appropriate resources to meet your needs on drug or therapy development for Candidiasis therapy.
Introduction to Candidiasis
Candidiasis, which is caused by Candida species, is a form of infection that is particularly concerning on a global scale. Invasive candidiasis, one of the more severe forms of the disease, is a leading source of healthcare associated bloodstream infections in the US, resulting in longer hospitalizations and greater expenses in the healthcare system. The rate of candidemia in the US has been stable at about 9 cases for each 100,000 people each year. Vulvovaginal candidiasis (VVC) is common among females with an estimated 138 million cases of recurrent VVC annually worldwide.
Drug Targets for Candidiasis
Candidiasis is challenging to treat and the therapeutic capabilities are restricted to a few classes of therapeutic options: polyene, echinocandin, and azole antifungals. Each subclass is associated with some issues problem such as side effects, low antifungal activity, and resistance, which impacts their clinical application. Therefore, further research to discover novel antifungal targets is necessary in order to design appropriate antifungal agents. There are some inhibitors for antifungal target proteins that are very likely helpful in the therapeutic of candidiasis.
- Targets in the cell wall: Inhibiting chitin synthase; Inhibiting GPI biosynthesis; Inhibiting chitin synthase;
- Targets in the cell membrane: inhibiting sphingolipid synthesis
- Targets in vesicle trafficking
- Targets in the drug efflux system
- Targeting a core stress response protein, Hsp90
- Targeting calcineurin
- Targeting lysine deacetylase
Fig. 1 Novel antifungal targets and their inhibitors. (Lu, H., et al., 2023)Vaccine Development of Candidiasis
One of the most efficient tools to avoid causing death and high rates of hospitalization will be improved and the vaccine will help control the spread of an infectious agent disease. The increasing rate of the mortality of drug-resistant fungal infections coupled with the rise in immunocompromised populations necessitates the urgent efforts to produce an effective fungal vaccine for the benefit of humanity.
Fig. 2 A schematic diagram showing experimental Candida vaccines. (Sahu, S.R., et al., 2022)Vaccines & Monoclonal Antibodies Against C.albicans Antigens
| Targts | Vaccine/Antibody | Development Stage |
|---|---|---|
| Als3 | rAls3p-N(vaccine) | Not determined |
| NDV-3(vaccine) | Phase Ⅰ clinical trial | |
| MAbC7(antibody) | Not determined | |
| Hsp90 | r-hsp90-CA(vaccine) | Not determined |
| pD-HSP90C(vaccine) | Not determined | |
| Mycograb | Phase Ⅲ clinical trial | |
| Eno1 | Mab12D9 | Not determined |
| CaS1(antibody) | Not determined | |
| Sap2 | Pev-7(vaccine) | Phase Ⅰ clinical trial |
| hybrid phage displaying Sap2 epitope SLAQVKYTSASSI(vaccine) | Not determined | |
| Hwp1 | Hwp1 glycopeptide conjugate (vaccine) | Not determined |
| MAb2-E8(antibody) | Not determined | |
| Hyr1 | Recombinant Hyr1 protein | Not determined |
| Mdh1p | Recombinant Mdh1p protein | Not determined |
Our Services
The company takes a proactive role and works directly and effectively with clients in providing customized, innovative therapeutic solutions for Candidiasis. We provide support throughout the entire development cycle ensuring efficiency and due diligence of the tailored caps.
Platforms of Candidiasis Therapy Development
Animal Models of Candidiasis
We pride ourselves in possessing a wealth of expertise pertaining to the creation and use of animal models that faithfully replicate the disease characteristics and therapeutic responses associated with Candidiasis. Such models augments the evaluation of novel therapies in terms of safety and efficacy.
| Non-Genetically Engineering Models | ||
|---|---|---|
| We provide an array of models designed to meet specific research requirements for Candidiasis. These models allow researchers to replicate and study the intricate biological processes associated with the disease. | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Non-human primates, Others | |
In addition, we offer a range of comprehensive animal model services that concentrate on specific signaling pathways and molecular targets.
If you are interested in our services, please contact us as soon as possible for more information.
References
- Lu, H., et al., "Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies." Adv Drug Deliv Rev, (2023). 199: p. 114960.
- Sahu, S.R., et al., "Vaccines against candidiasis: Status, challenges and emerging opportunity." Front Cell Infect Microbiol, (2022). 12: p. 1002406.
- Feng, Z., et al., "Promising immunotherapeutic targets for treating candidiasis." Front Cell Infect Microbiol, (2024). 14: p. 1339501.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.